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Abstract
Background: Encrustation of ureteral double J stents is a common complication that may affect its removal. The
aim of the proposed study is to evaluate the efficacy and safety of a new oral composition to prevent double J
stent encrustation in indwelling times up to 8 weeks.
Methods: A double-blinded, multicenter, placebo-controlled trial was conducted with 105 patients with indwelling
double J stents enrolled across 9 public hospitals in Spain. The patients were randomly assigned (1:1) into
intervention (53 patients) or placebo (52 patients) groups for 3 to 8 weeks and both groups self-monitored daily
their morning urine pH levels. The primary outcome of analysis was the degree of stent ends encrustation, defined
by a 4-point score (0 – none; 3 – global encrustation) using macroscopic and electron microscopy analysis of
crystals, after 3 to 8-w indwelling period. Score was exponentially transformed according to calcium levels.
Secondary endpoints included urine pH decrease, stent removal, and incidence of adverse events.
Results: The intervention group benefits from a lower global encrustation rate of stent ends than placebo group
(1% vs 8.2%; p < 0.018). Mean encrustation score was 85.12 (274.5) in the placebo group and 18.91 (102.27) in the
intervention group (p < 0.025). Considering the secondary end points, treated patients reported greater urine pH
decreases (p = 0.002). No differences in the incidence of adverse events were identified between the groups.
Conclusions: Our data suggest that the use of this new oral composition is beneficial in the context of ureteral
double J indwelling by decreasing mean, as well as global encrustation.
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Background
Double-J ureteral stents [1] are one of the most common
indwelling ureteral devices used for treatment of ob-
structive uropathy, postoperative of ureteropyelic sten-
osis and renal transplantation [2, 3]. Their effectiveness
for renal collecting system drainage has been proven [4]
and their characteristic design, with both renal and vesi-
cal J-shaped curl ends, prevents stent migration [1].
However, double J ureteral stents have also been related
to patient discomfort, pain, urinary tract infection and
encrustation [4, 5].
A prolonged indwell time of stents, as well as a history
of nephrolithiasis and urinary infections may result in
encrustation of ureteral stents, and will lead to the use
of endourological techniques, extracorporeal lithotripsy
or open surgery to resolve these conditions [6–8].
Film-formation is a multistep process; shortly after the
stent insertion, different organic molecules adhere to its
surface forming conditioning film [9, 10] and the pres-
ence of bacteria attached to the stent surface was consid-
ered essential for the formation of struvite and
hydroxyapatite crystals [4, 11]. Nonetheless, recent stud-
ies have demonstrated that the presence of bacteria is
not compulsory and conditioning film, together with
urine pH, might play a bigger role in Ca and Mg phos-
phate precipitates forming hydroxyapatite and brushite
crystals, which result in stent encrustation [12]. Oher
factors, such as urine pH and supersaturation, play an
important role and several studies have shown that
higher urine pH values are found in blocker patients
(those in which stent obstruction is observed) compared
to non-blocker ones [10, 13, 14]. Thus, stent encrust-
ation could be minimized if urine composition is altered
by reducing the urine alkalinisation and increasing the
urine excretion of crystallization inhibitors.
The oral composition studied contains both urine acidifier
and crystallization inhibitors, such us L-methionine (an es-
sential amino acid recommended by the EAU Guidelines on
Urolithiasis with acidifier properties for the treatment of in-
fectious stones) and phytin (a phytate salt with demonstrated
inhibitory properties of calcium stones) as active compo-
nents. L-methionine directly reduces/acidifies urine pH [15,
16], whereas crystallization inhibitors [17] decrease the risk
of renal stone formation [18, 19].
On the other hand, the pH meter is a medical device,
which has been validated with patients [20, 21], designed
for urine pH self-monitoring, enabling patients to easily
control urine pH on their own and its applicability may
be extended to other urological pathologies where urin-
ary pH plays an important role, such as acid-base imbal-
ance diseases, urinary tract infections, cystitis, painful
bladder syndrome or stent encrustation [22–24].
The main goal of this study was to assess the potential
in preventing double-J stent encrustation of a new oral
composition in a study with indwelling times between 3
and 8 weeks, as well its efficacy and safety. Secondary
objectives included urine pH decrease, stent removal, in-
cidence of adverse events, patient’s compliance and phy-
sician’s and patient’s satisfaction. The promising data
obtained pave the way to further investigations for the




A prospective, parallel, double-blinded, randomized and
placebo-controlled trial was conducted between 9th
January 2018 and 9th July 2018 at 9 public hospitals in
Spain, in accordance with the Declaration of Helsinki,
ethical standards, current legislation and GCPs. The
study was approved by local Ethics Committees, and in-
formed consent was obtained from all patients prior to
their enrolment in the study. This study adheres to
CONSORT guidelines.
Subjects
The recruitment period was from January to July 2018.
Inclusion criteria comprised patients aged 18 and older,
capable of daily self-monitor their urine pH, who were
willing to participate and had recently implanted a
double J stent (less than a week ago) or programmed for
it, with an expected indwelling time below 8 weeks, max-
imum period of time allowed for stent indwelling ac-
cording to the Ethics Committee. Exclusion criteria
comprised patients with programmed stent removal
prior to 3 weeks from the inclusion visit, pathologies in-
compatible with the consumption of the oral compos-
ition, and uric or cystinuric patients in which different
pH control recommendations are needed (Fig. 1). All pa-
tients finally enrolled were stone-formers with an
indwelled double J stent for urine derivation due to
endourological procedures.
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Locations of data collection
The study was conducted in the following nine [9] public
hospitals in Spain: 1) Hospital Universitari de Bellvitge,
Barcelona; 2) Hospital Universitario La Paz, Madrid; 3)
Hospital Universitario Rio Hortega, Valladolid; 4) Funda-
ció Puigvert, Barcelona; 5) Hospital Universitario Clínico
San Cecilio, Granada; 6) Hospital Universitario Virgen de
Valme, Sevilla; 7) Hospital Álvaro Cunqueiro, Vigo; 8)
Hospital Universitario y Politécnico La Fe, Valencia; 9)
Complejo Hospitalario Universitario de Santiago de
Compostela (CHUS), Santiago de Compostela.
Treatment description
Subjects were randomly assigned in a 1:1 ratio to receive
an oral composition (containing a urine acidifier and
crystallization inhibitors) or placebo as investigators in-
cluded them in a password-protected computer database
with a pre-programmed randomization list with blocks
of 2 to 4. The CRO (BioClever, Barcelona, Spain) gener-
ated the random allocation sequence, the hospitals en-
rolled the participants and the investigators assigned the
participants to interventions. The oral composition arm
consisted in oral administration of three capsules per
day (1-1-1) to maintain the urine pH under 6.2, a pre-
ventive pH value, and increase the urine excretion of
crystallization inhibitors to avoid stent encrustation [15,
25]. Patients in placebo arm received a treatment con-
sisting in oral capsules with the same organoleptic and
posology characteristics as the investigational com-
pound. Both arms used a portable medical device (Lit-
Fig. 1 Patient flow chart and allocation
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Control® pH Meter) to self-monitor their urinary pH
every morning, and identical hygienic-dietary indications
for stent care were given to all participants.
Follow-up evaluation
Intervention and pH self-control duration ranged from 3
to 8 weeks depending on the time-lapses between the
baseline visit and the stent removal. Once removed, the
process consisted in submerging the stent ends in thy-
mol to cleanse, gently letting them air dry over paper.
This procedure prevents the growth of microorganisms
and the crystallization progression to guarantee the cor-
rect encrustation evaluation. All analyses were carried
out in a central laboratory (Laboratory of Investigation
in Renal Lithiasis, Universidad de las Islas Baleares-
IUNICS). Stents ends were cut and processed to exam-
ine the renal and vesical ends separately, in a
homogenous fashion among the distinct enrolled centres
according to protocol instructions.
Outcome measures
Primary outcome
The presence and degree of stent encrustation. A 4-level
score was employed to determine the degree of encrust-
ation based on surface and thickness (mm), (0: without
inlay; 1: sporadic calcifications, < 2 mm; 2: calcification
of wide areas, ≥ 2 mm; 3: global encrustation (=complete
block) (Fig. 2). The 0 score was divided in 2 categories:
with or without the presence of conditioning film; this
division does not affect the final value of encrustation.
An exponential transformation of the score was add-
itionally applied because calcium concentration ratios,
measured by Arsenazo III spectrophotometry, were fol-
lowing log scale. A dichotomous variable for global en-
crustation (score 3) was created and used in the stent
ends database. The type and size of crystals were
assessed by SEM and micro-analysis by dispersive energy
of X-Ray, and the degree of global encrustation of each
end was measured using ICP-AES spectroscopy (Fig. 2).
The type of deposit, presence of bacteria, and the size
and nature of the crystals were identified using scanning
electron microscopy (Hitachi S 3400 N), coupled to a
microanalysis by X-Ray dispersive energy (Bruker AXS
GmbH, Karlsruhe, Germany).
Secondary outcomes
Urinary pH reduction together with duration and
method of the stent extraction intervention were re-
corded as secondary outcomes. First morning void as a
spot urine sample, was performed daily. Specifically for
Fig. 2 Encrustation measurement from 0 (nothing) to 4 (global encrustation) measured by radiographic image, microscopic view and electron
microscope of the stent
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the quantification of urinary pH change during the study
period, the following was registered: i) an hospital meas-
ure of urine pH was considered as day 0; ii) mean domi-
ciliary values of urine pH from days 1–3 were
considered the baseline of pH self-monitoring data; iii)
pH domiciliary values at day 21 and iv) mean domiciliary
pH values from day 4 to the end of indwelling period
(21 to 56 days). The baseline was compared to pH at day
21 and to the mean pH values for the total indwelling
period. Duration and method of the stent extraction
intervention data were also recorded as secondary out-
comes. Risk factors for encrustation development (days
with implanted stent and number of previous implanta-
tions), stent-related symptoms, previous uropathies and
sociodemographic data were also recorded to be studied
as factors or covariates. Compliance was measured by
counting returned medication, and consumption of
more than 80% of the capsules was considered good
adherence.
Statistical analysis
A sample size of 47 evaluable patients per treatment
group would provide approximately 80% power to detect
a reduction with an effect size of 0.6 in the encrustation
score in either intervention group versus placebo using a
Mann-Whitney U test. The sample was increased to 105
participants considering a 10% of dropouts. Demographic
and baseline characteristics and safety and tolerability data
were summarised using descriptive statistics. The primary
endpoint, the difference in the encrustation score between
groups, was assessed using a Fisher exact test for the cat-
egorical variable global encrustation and a Mann-Whitney
U test for the encrustation scores, which were also ana-
lysed using Generalized Linear Models for a Tweedie dis-
tribution with a logarithmic link, including treatment, sex,
baseline pH < 6 and indwelling duration > 39 days as fixed
factors and age as a covariate. Mean differences and 95%
confidence limits were calculated for all comparisons be-
tween groups. Global encrustation was analysed using a
logistic regression model that included treatment, sex,
baseline pH < 6, first implantation, indwelling duration
and age. Secondary end points as pH reduction, interven-
tion time for stent removal or patient satisfaction were an-
alyzed using one-way analysis of variance. Statistics for all
tables, figures, and graphs were calculated from the total
number of valid cases. All statistical analyses were per-
formed on the intention-to-treat population using SPSS
22.0 software for Windows.
Results
A total of 105 patients with a mean (SD) age of 51.6
(13.1) years were analysed (Fig. 1 and Table 1), with 198
stent ends collected from 99 subjects who wore them for
an average time of 37.54 ± 13.9 days. Placebo and
Table 1 Characteristics of the study population
Placebo group Nutraceutical group Total p-
valueN (%) Mean (SD) N (%) Mean (SD) N (%) Mean (SD)
Sex
Male 28 (53.8) 30 (56.6) 58 (55.2) 0.85
Female 24 (46.2) 23 (43.4) 47 (44.8)
Total 52 (100) 53 (100) 105 (100)
Age 51.5 (13.2) 51.7 (13.0) 51.6 (13.1) 0.95
Previous obstructive uropathy 19 (36.5) 21 (39.6) 40 (38.1) 0.84
Previous stenting 19 (36.5) 22 (41.5) 41 (39) 0.69
Urolithiasis as cause of current implantation 41 (78.8) 41 (77.4) 82 (78.1) 0.85
Type of calculi
Calcium oxalate 19 (46.3) 21 (51.2) 40 (48.8) 0.80
Others 22 (53.7) 20 (48.7) 42 (51.2)
Total 41 (100) 41 (100) 82 (100)
Stent material
Polyurethane 23 (44.3) 20 (37.7) 43 (40.9) 0.45
Silicone 1 (1.9) 0 (0) 1 (1)
Percuflex 28 (53.8) 33 (62.3) 61 (58.1)
Implantation period (days) 39.7 (14.9) 35.4 (12.7) 37.54 (13.9) 0.12
Basal urinary pH 43 (100) 6.2 (0.6) 44 (100) 6.3 (0.8) 87 (100) 6.3 (0.7) 0.62
SD standard deviation
Group homogeneity at baseline
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intervention group were comparable at baseline (see de-
tailed parameters at Table 1). Concerning the presence
or not of global encrustation as primary outcome, eight
stent ends (8.2%) showed global encrustation in the pla-
cebo group and 1 (1.0%) in the intervention group (R.R.:
8.2 [1.04–64.06]; p = 0.018) in a period of 3–8 weeks,
obtaining the same results than other authors in three
previous studies [26–29]. The encrustation degree scores
by stent end are detailed in Table 2; the analysis of all
the double J stent ends resulted in encrustation levels of
85.12 (274.5) in the placebo group, and of 18.91 (102.27)
in the intervention group (p = 0.025); difference (95%
IC) is 66.21 (8.37, 124.06). These results demonstrate an
8-fold reduction in global encrustation for the experi-
mental group, together with a striking reduction in the
degree of such encrustation in every analysis, when con-
sidering distinct stent ends or the sum of all ends.
As for secondary outcome, the reduction in urinary
pH from the baseline or day 1 to values obtained after
all the indwelling period was significantly greater in the
intervention group (Table 2). These data show that the
administration of the new oral composition is effective
in decreasing the urinary pH as a preventive measure for
stent calcifications.
Binary logistic regression model of all stent ends global
encrustation showed a OR in the placebo group of 20.61
[95% IC: 1.66 –* 256,2; p = 0.019] emerging as protective
factors age > 47, first implantation and baseline pH < 6
and favoring encrustation would be male gender (Fig. 3).
Four (22%) of 18 patients whose mean pH level during
indwelling was greater than 6 showed global encrust-
ation in 7 stent ends and 1 (1.7%) of 58 patients with
lower pH levels showed this outcome in 1 stent end (RR:
12.9 [1.4–296.7]; p < 0.012).
Spearman correlation between indwelling time in days
and encrustation score was ρ = 0.212 (p < 0.036) for the
kidney end and ρ = 0.153 (p < 0.13) for the bladder end.
When separated by study group, r2 of encrustation score
at kidney end by indwelling time was 0.079 for the pla-
cebo group and 0.018 for the nutraceutical group.
The total amount of calcium deposited in stents with
encrustation scores of 3 was thousand times greater than
the amount in stents with score 1 (Table 3), justifying an
exponential transformation of the score. Table 4
summarize the types of scale and the magnitude of the
deposits; in the 28.3% of the stents no deposit was ob-
served in the bladder part, while in the renal part there
were no deposits in 41.4%.
The deposits consist mainly of organic matter only
(12.1% bladder part - 8.1% renal part) or small crystals
of calcium oxalate monohydrate (COM or COM+COD)
developed on top of a layer of organic matter. In
addition, bacteria were on the surface of the bladder part
in 4.0% of the stents and on the renal part in 2.0% of the
stents. In all cases, bacteria were on top of the layer of
initially deposited organic matter (Fig. 4).
Table 2 Between groups analysis
Placebo Nutraceutical Inference
Mean (SD) n Mean (SD) n Difference/OR (95% CI) p
Encrustation
Kidney stent end 64.73 (241.74) 49 7.66 (23.69) 50 57.07 (−11.1, 125.25) 0.89
Bladder stent end 105.51 (304.99) 49 30.16 (142.52) 50 75.35 (−19.3, 170.00) 0.65
Sum of stent ends 170.24 (513.58) 49 37.82 (159.24) 50 75.35 (−19.28, 169.99) 0.65
Maximum of stent ends 105.69 (304.93) 49 30.34 (142.49) 50 132.43 (−18.62, 283.47) 0.67
Encrustation adjusted for baseline urine pH
Sum of stent ends 78.34 (158.44) 39 11.11 (32.97) 37 67.23 (19.18, 115.29) 0.006
Encrustation adjusted for baseline urine pH, age, gender and indwelling duration
Sum of stent ends 57.57 (122.09) 39 18.27 (48.42) 37 39.0 (2.02, 76.57) 0.039
Urine pH
pH reduction baseline (24 h) to day 21 0.39 (0.7) 28 0.86 (0.78) 32 −0.47 (−0.85, −0.084) 0.018
pH reduction days 1–3 to day 21 0.17 (0.49) 36 0.54 (0.58) 36 −0.37 (−0.62, −0.11) 0.005
pH slope −.0061 (.013) 40 −.014 (0.02) 39 0.008 (0.00006, 0.016) 0.042
Stent removal
Removal surgery time (min) 13.8 (30.5) 52 7.23 (13.5) 52 0.76
Removal surgery time (adjusted, min) 40.9 (5.8) 52 9.5 (4.15) 52 < 0.001
N % n % Odds ratio
Stent removed at first attempt 47 48.5 50 51.5 2.66 [0.49–14.37] 0.44
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The non-continuous deposits of thickness greater than
1 to 2 mm, mainly consisted of hydroxyapatite (1.1% in
the bladder part), hydroxyapatite+ ammonium magne-
sium phosphate (1.0% in the renal part) and uric acid
(3.0% in the bladder and 2.0% in the renal part, Fig. 5).
Larger depositions, which can cause obstructions and/or
complete block, were mainly brushite and hydroxyapa-
tite (3.0% in the renal part and 4.0% in the bladder part,
shown in Fig. 5), and magnesium ammonium phosphate
(2.0% in the bladder part, Fig. 6). Although the deposits
of magnesium ammonium phosphate are clearly of bac-
terial colonization origin, no bacteria were detected in
the crystals.
Fifteen patients (37.5%) in the placebo group and 12
(30%) in the intervention group took less than 80% of
prescribed doses (p = 0.6). Twelve patients (11.4%) in the
placebo group and 14 (13.3%) in the intervention group
failed to provide valid pH measures due to inadequate
use of the device.
Three patients in the placebo group reported mild ad-
verse events (2 nausea and 1 hot flashes) and 3 in the
intervention group (1 diarrhea, 1 blurry vision and 1 dys-
pepsia). Two patients in the placebo group discontinued
the study due to adverse events. No additional measures
Fig. 3 Multivariate model of Double J ureteral stent encrustation
Table 3 Amount of calcium deposited on the stent
Magnitude of the scale Id Calcium deposit
Type 1 49 bladder 0,95 nmol / cm
59 bladder 1,21 nmol / cm
43 renal 0,84 nmol / cm
49 renal 0,42 nmol / cm
50 renal 0,85 nmol / cm
Type 3 41 bladder 330 nmol / cm
3 bladder 346 nmol / cm
72 bladder 244 nmol / cm
3 renal 329 nmol / cm
Table 4 Characterization for stents encrustation Bladder (N =
99) and Renal (N = 99) ends
Percentage (%) of encrustation in stents
Bladder end Renal end
0 1 2 3 0 1 2 3
no deposit 28.3 41.4
OM 12.1 8.1
COM 24.2 27.3
COM + COD 14.1 11.1
BRU 2.0 1.0 2.0
HAP 1.0 1.1 1.0
HAP + BRU 1.0 3.0 3.0
UA 3.0 2.0
UA + COM 1.0 1.0
bacteria 4.0 2.0
HAP + PAM 2.0 1.0
BRU + COD 1.0 – – – –
AU 1.0 – – – –
OM organic matter; COM calcium oxalate monohydrate; COD calcium oxalate
dihydrate; BRU brushite; HAP hydroxyapatite; UA uric acid; PAM ammonium
magnesium phosphate; AU ammonium urate
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needed to be taken for the rest of the patients due to ad-
verse effects. Six patients in the placebo group and 6 pa-
tients in the intervention group were prescribed with
antibiotics due to positive baseline urine cultures.
Discussion
The calcification phenomenon has relevant clinical con-
sequences that may compromise stent removal. When
indwelling time increases, encrustation prevalence in-
creases proportionally [7, 26, 29, 30] and global encrust-
ation can occur, leading to the use of endourological
techniques, extracorporeal lithotripsy or open surgery to
resolve these conditions [8, 31]. Although heavily
encrusted stents clearly do pose significant problems,
minor encrustations can also challenge the endourolo-
gist, particularly if occurring frequently and repetitively
[27]. Some publications indicate that the mere presence
of a biofilm in the stent increase patient’s discomfort
and lower urinary tract symptoms (LUTS) [11, 32],
which may increase inflammation, tissue damage and
eventually affect stent removal. To this date, no oral
treatment to prevent or decrease stent encrustation have
been proposed.
The degree of stent encrustation was strikingly re-
duced in the experimental group treated with the oral
composition, when considering each stent end separated
or their sum, as well when adjusting the data for baseline
urine pH, age, sex, previous implantation and indwelling
duration. Particularly for those stents with a global en-
crustation value, the difference between the intervention
group and placebo yielded a relative risk of 8.2 and this
effect was enhanced by baseline pH level.
The microscopic study of the stents indicated that or-
ganic matter in the urine (macromolecules or cellular
debris) is first deposited on the stent forming a layer
(conditioning film) that is several micrometers thick
(Fig. 2, encrustation definition 0(f)). The thickness and
composition of the conditioning film depend on the
urine composition of the patient.
For patients with non-lithogenic urine (no hypercalci-
uria, no hyperoxaluria, no hypocitraturia, and a urinary
pH between 5.5 and 6.2) and no bacterial colonization of
the urine, organic matter deposits can occur, and act as
heterogeneous nucleants that support the growth of
COM crystals over 2 to 3 months [33, 34]. This growth
is very slow, forming only a thin layer (thickness of sev-
eral micrometers) (Fig. 2). The underlying mechanism
may be analogous to the formation of COM stones in
renal cavities [33]. If a patient has a high level of urinary
calcium, then COD crystals may develop.
If bacteria are present, they can colonize the stent sur-
face and grow while embedded in the initially deposited
organic matrix (Fig. 4). The biofilm resulting from infec-
tion by urease-producing bacteria increases the urinary
pH and leads to the formation of carboxyapatite and
magnesium ammonium phosphate crystals (Fig. 6).
Fig. 4 Surface of a stent covered by an organic matter layer (conditioning film) in which colonies of bacteria have developed (encrustation classified as 1)
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Depending on bacterial activity, these crystals can range
from small deposits to large concretions, and, in many
cases, they obstruct the inflow and outflow through the
stent, and make the stent extraction much more difficult
for the urologist. The most common bacteria in these
deposits is P. mirabilis [35, 36]. It is interesting to ob-
serve how the presence of bacteria on the organic matter
layer has been detected, forming the biofilm, but they
have not been identified on the magnesium ammonium
phosphate crystals, which are clearly infectious. This can
be explained considering that the bacteria are installed
in the areas between the organic matter and the surface
of the crystalline deposit, thus being also protected from
the action of antibiotics.
For urine with a pH higher than 6.2 and no bacterial
colonization, significant deposits of calcium phosphate
can develop depending on the specific conditions. In
particular, when the urine has a high calcium concentra-
tion, a citrate deficit, and a pH greater than 6.2, large de-
posits of brushite can build (Fig. 6) [33, 34]. Under these
conditions, large COD crystals can also occur. When the
calcium and magnesium concentrations are low, large
hydroxyapatite deposits can develop. For urine with a
pH less than 5.5, major deposits of uric acid can develop
(Fig. 5). It is important to point out that, in urinary pH
values between 5.5 and 6.2, the crystalline development
occurs at such a rate that does not allow the develop-
ment of large deposits and consequent obstructions.
Fig. 5 Surface of a stent covered by dihydrate uric acid deposits, classified as 2. (A) Optical image, (B) Scanning electron microscopy image
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The multivariate models showed that the formation of
deposits in the double J stent ends is a multifactorial
process dependent on patient’s previous implantation,
duration of the implantation period, baseline pH level,
and the use of an oral composition (Fig. 3). Both oral com-
position and baseline pH are independent factors that pre-
vent stent encrustation. A mean pH greater than 6.2
during indwelling time increased 12.9 times the risk of
global encrustation of a stent end. In addition, the experi-
mental group has a higher urinary pH decrease from base-
line to the end of the indwelling period. The fact that the
oral composition studied consists in an acidifier (L-me-
thionine) plus an inhibitor (phytin) may account for it,
since both components have a synergic effect on reducing
urine pH and inhibiting urine crystallization, respectively,
which may prevent encrustation [12, 18, 19].
A better adherence to treatment could add more value
to the final data; 37.5% of patients in the placebo group
and 30% in the experimental took less than 80% of pre-
scribed doses. Additionally, both intervention and
placebo groups lowered their urine pH levels; this may
be since hygienic-dietary indications for stent care were
given to all participants and to the daily urine pH self-
monitoring carried out by both groups. Patients scored
their satisfaction with the pH meter with an average of 8
over a 0 to 10 scale.
This study has some limitations. It would be useful if
metabolic urine studies were performed prior and after
the administration of the oral composition and/or the
placebo. However, most of the cases included in our trial
came from the emergency room (ER) or from peri-
surgical situations, making difficult to collect urine sam-
ples for metabolic analysis. In addition, it was considered
a possibility of bias in the urinary metabolic parameters
due to such hospitalization and surgical interventions. It
is a pioneer study, consisting in the first controlled, pro-
spective, randomized and multicenter trial collecting and
analyzing 198 stent ends, and for this first assumption of
the potential benefits of the proposed therapy, one could
consider up to 56 days a short indwelling time. It asks
Fig. 6 Surface of a stent covered by ammonium magnesium phosphate + hydroxyapatite deposits (A) Optical image, (B) Scanning electron
microscopy image. Surface of a stent covered by brushite + hydroxyapatite deposits (C) Optical image, (B) Scanning electron microscopy image
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for next steps, which will be a study comprising longer
periods to validate the treatment.
Overall, the results observed reveal a significant de-
crease in global encrustation in the intervention group
even in the short period of time applied in this study.
We also observe a higher urinary pH decrease in the ex-
perimental group, being lower urinary pH a protective
factor against encrustation. To our knowledge this is the
first report of a potential oral treatment to prevent
double J ureteral stent encrustation by changing the
urine composition of the patients.
Conclusion
The use of an oral composition in patients indwelling a
double J ureteral stent resulted in fewer stent encrustations.
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